![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, January 26, 2009 3:24:57 AM
http://www.cnbc.com/id/28813740
Excerpt:
"Personalized medicine uses everything from height and weight to gene and gene-expression information to treat patients. Celera and Abbott are trying to develop molecular diagnostic products to aid in the process. The two firms recently updated their deal, which should lower Celera’s operating expenses and give the company room to launch products outside the joint venture with Abbott. So even if a merger never happens, Celera might stand on its own as a solid investment."
More here:
http://www.madmoneyrecap.com/madmoney_nightlyrecap_012309_2.htm
Excerpt: "... personalized medicine requires a lot of diagnostic tests… and that is what Celera is working on with Abbott Labs… disease detection, assessing an individuals pre-disposition to certain diseases… monitoring the progression of a disease… and choosing the right therapy…. remember President Obama loves this stuff… because it saves money on health care costs down the line..."
http://www.dnaprint.com/welcome/corporate/
http://www.dnaprint.com/welcome/pipeline/
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM